What’s more, a closer look showed an even higher approval rate. This year so far, 96% of new molecular entities– industry jargon for drugs that have never been approved for any use before – that have been submitted to the FDA have reached the market. For anyone who was watching the FDA a decade ago, that’s just shocking. Good or bad, it’s a radical change.